ESR1 and breast cancer: Genetic mutations can lead to BC and have been experimentally linked to some tumor markers, including progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor type 2 (HER2) statuses, which are used clinically in the classification of BC [5].